Clinical Trial Update: A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update comparing pharmacokinetics, safety, and immunogenicity of RPH-030 and Vectibix (panitumumab) in patients with metastatic colorecta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• RPH-030
• Vectibix (panitumumab)

Snippet

Sponsor: R-Pharm | Conditions: Metastatic Colorectal Cancer | Phase 1 | Status: RECRUITING